STM JOURNALS

Journal of
Nanoscience, Nanoengineering & Applications

ISSN: 2231-1777 (Online)
ISSN: 2321-5194 (Print)
Volume 15, Issue 1, 2025
January–April
DOI (Journal): 10.37591/JoNSNEA

https://journals.stmjournals.com/jonsnea

Review JoNSNEA

Nanotechnology-Driven Drug Delivery: A Comprehensive Review of Current Trends and Future Directions

Mehak Khanum[1,*], Jennifer S.[1], Zaid Khan[2]

Abstract

Nanotechnology has revolutionized drug delivery systems, offering profound advancements in precision, efficiency, and targeted therapeutic interventions. This review examines the revolutionary influence of nanotechnology on medical therapies, focusing on advancements, such as precise drug delivery, improved solubility, and responsive treatment systems. These advancements have significantly improved treatment efficacy and minimize side effects, particularly in oncology and chronic disease management. The development of nanoparticles designed for specific cell targeting and environmental responsiveness has been pivotal in enhancing therapeutic outcomes. Although significant progress has been made, obstacles like biocompatibility, scalable manufacturing, and regulatory challenges persist. Future advancements will depend on addressing these issues, with ongoing research needed to enhance nanoparticle targeting, ensure safety, and streamline production. The integration of artificial intelligence and nanorobotics presents promising opportunities for optimizing treatment precision and personalization. Bridging the gap between research and clinical application through improved preclinical models, adaptive regulatory frameworks, and global collaborations will be essential in realizing the full potential of nanotechnology for more effective and personalized medical treatments.

Keywords: Nanotechnology, drug delivery systems, targeted drug delivery, nanoparticles, regulatory challenges, AI-driven systems, FDA-approved nanomedicines

***Author for Correspondence**
Mehak khanum
E-mail: khanummehak12@gmail.com

[1]Research Scholar, Department of Pharmaceutics, Faculty of Pharmacy, St Jhon's Pharmacy College, Bangalore 560104, Karnataka, India.
[2]Research Scholar, Department of Pharmacy Practice, Faculty of Pharmacy, Aditya Bangalore Institute of Pharmacy Education and Research, Bangalore, Karnataka, India.

Received date: December 23, 2024
Accepted date: December 30, 2024
Published date: January 04, 2025

Citation: Mehak Khanum, Jennifer S, Zaid Khan. Nanotechnology-Driven Drug Delivery: A Comprehensive Review of Current Trends and Future Directions. Journal of Nanoscience, Nanoengineering & Applications. 2025; 15(1): 24–46p.

INTRODUCTION

Significance of Nanotechnology in Modern Medicine

Advanced Diagnostics

Nanotechnology greatly improves diagnostic methods through the creation of highly sensitive biosensors. These sensors, which utilize nanomaterials, offer improved detection of biological markers with exceptional accuracy. This heightened sensitivity is pivotal for early disease detection and ongoing monitoring, thereby supporting more effective treatment strategies [1].

Targeted Drug Delivery

One of the most profound applications of nanotechnology in modern medicine is in the realm of targeted drug delivery. Nanoparticles can be

precisely engineered to deliver therapeutic agents directly to specific cells, such as cancer cells. This targeted strategy improves treatment effectiveness while reducing side effects, enabling more accurate and efficient therapeutic solutions [2].

Innovations in Cancer Treatment

Nanotechnology has driven remarkable progress in the treatment of cancer. Nanostructures can serve as carriers for chemotherapeutic agents, optimizing their delivery and efficacy. Furthermore, these nanomaterials are instrumental in gene therapy and photodynamic therapy, where they facilitate the targeted destruction of cancer cells while sparing healthy tissues. Additionally, nanomaterials are increasingly used as molecular imaging agents, aiding in the diagnosis and monitoring of tumor growth [3].

Regenerative Medicine

Nanotechnology revolutionizes regenerative medicine by enabling nanostructured scaffolds that interact at the molecular level, enhancing tissue repair and healing. Its customizable properties allow tailored solutions, improving patient outcomes [4]. Beyond regeneration, nanotechnology drives innovations in diagnostics, targeted therapies, and overall healthcare, offering transformative advancements in treatment efficacy and patient care [5].

Importance of Nanotechnology-Driven Drug Delivery

Nanotechnology-driven drug delivery systems are crucial in modern medicine, enhancing the efficacy and safety of therapies [6]. They offer advantages, such as improved drug solubility and stability, precise targeting of specific cells (e.g., cancer cells), reduced off-target effects, and increased therapeutic efficacy, leading to safer treatments [7].

Scope and Objectives

This review encompasses the diverse applications of nanotechnology in drug delivery, with a focus on:

- The utilization of nanoparticles as drug carriers.
- Targeted delivery mechanisms involving ligand-receptor interactions.
- The creation of stimuli-responsive nanocarriers enables controlled and precise drug release;
- The use of nanomaterials facilitates the efficient delivery of genes and nucleic acids; and
- The incorporation of theranostic nanoplatforms enables simultaneous diagnosis and treatment [8].

The Primary Objectives of This Review Are to

1. Offer a detailed overview of recent progress in drug delivery systems powered by nanotechnology;
2. Examine the distinct characteristics of nanomaterials, such as their high surface area, tunable size, and ability to be functionalized, which make them ideal for drug delivery applications;
3. Emphasize how nanotechnology can overcome the limitations of traditional drug delivery methods by improving targeting accuracy, enhancing bioavailability, and reducing systemic side effects; and
4. Explore the clinical translation and prospects of nanomedicine [9].

By fulfilling these objectives, this review aims to underscore the transformative role of nanotechnology in revolutionizing drug delivery systems and its potential to enhance patient outcomes across various therapeutic domains, including oncology, infectious diseases, and chronic conditions [10].

Fundamentals of Nanotechnology in Drug Delivery

Nanotechnology entails the manipulation of matter at the nanoscale (1–100 nanometers), combining concepts from physics, chemistry, biology, and engineering. It leverages the unique properties of

materials at this scale, leading to innovative applications across industries, particularly in medicine [11].

Applications in Drug Delivery Systems

Nanotechnology has brought transformative advancements to drug delivery systems, enhancing the efficacy and safety of therapeutic agents. Key applications include the following.

Targeted Drug Delivery

Nanoparticles can be meticulously designed to target specific cells or tissues, such as cancer cells, reducing off-target effects and boosting therapeutic effectiveness. This targeted delivery approach allows for higher drug concentrations at the site of action while reducing systemic exposure and associated side effects [12].

Improved Solubility and Stability

A common challenge in drug development is the poor solubility and stability of many therapeutic agents. Nanotechnology can solve this problem by improving the solubility of drugs, which helps them get absorbed better and work more effectively. Nanocarriers can enclose the drugs, protecting them from breaking down and ensuring they are delivered more efficiently [13].

Controlled Release Mechanisms

Nanotechnology enables the creation of drug delivery systems capable of controlled release. Stimuli-responsive nanocarriers are engineered to react to specific environmental factors like pH, temperature, or light, releasing their therapeutic contents at the right time and place. This precise control over drug release improves therapeutic outcomes [14].

Combination Therapies

Nanoparticles can be designed to carry several therapeutic agents at once, enabling combination therapies that target multiple pathways in disease processes, especially in cancer treatment.

This approach enhances treatment effectiveness and helps to overcome drug resistance mechanisms.

Imaging and Diagnostics

Nanotechnology advances imaging and diagnostics by increasing contrast and specificity in imaging techniques. Nanoparticles serve as contrast agents, enabling improved early disease detection and monitoring through enhanced imaging modalities.

Nanotechnology-driven drug delivery systems represent a significant advancement in medicine, offering innovative solutions to enhance drug efficacy, reduce side effects, and improve patient outcomes through targeted, controlled, and efficient delivery methods [15].

Mechanisms of Nanoparticle-Mediated Drug Delivery

Nanoparticles interact with biological systems through several distinct mechanisms that facilitate targeted drug delivery. The following outlines key approaches:

Passive Targeting

Nanoparticles can accumulate in tumor tissues passively because of the enhanced permeability and retention (EPR) effect, which allows them to enter and stay within tumors more easily. The abnormal and often leaky vasculature characteristic of tumors allows nanoparticles to extravasate into the tumor interstitium. Furthermore, the inefficient lymphatic drainage within tumors contributes to the retention of these nanoparticles [16].

Active Targeting

By modifying the surface of nanoparticles with targeting ligands like antibodies, peptides, or small molecules, active targeting can be achieved, directing the nanoparticles to specific cells or tissues. These ligands bind selectively to receptors that are overexpressed on tumor cells or tumor blood vessels, improving the accuracy of drug delivery to the targeted site [17].

Transcytosis

Nanoparticles can traverse biological barriers, such as the blood-brain barrier (BBB), via transcytosis. This mechanism involves the transportation of nanoparticles across endothelial cells through vesicular transport. By altering surface charge or conjugating nanoparticles with cell-penetrating peptides, they can be engineered to undergo adsorptive-mediated transcytosis [18].

Carrier-Mediated Transport

Nanoparticles can exploit carrier-mediated transport systems to cross biological barriers. By mimicking the structure of endogenous molecules that utilize specific transporters, nanoparticles can be actively transported across barriers such as the BBB [19].

Stimuli-Responsive Drug Release

Nanoparticles can be designed to release therapeutic agents in response to specific triggers, like changes in pH, redox potential, or enzyme activity – factors that are often altered in diseased conditions. This stimulus-triggered drug release reduces off-target effects and improves the effectiveness of the treatment.

By leveraging these mechanisms, nanoparticles enhance the delivery of therapeutic agents to target sites, improve drug solubility and stability, and optimize therapeutic outcomes across a range of diseases, including cancer, cardiovascular disorders, and neurological conditions [20].

Types of Nanocarriers

Nanocarriers in targeted drug delivery nanocarriers are advanced delivery systems designed to transport therapeutic agents to specific body sites, enhancing treatment efficacy and safety. The major types of nanocarriers are:

1. Liposomes are spherical vesicles made from lipid bilayers that enclose both hydrophilic and hydrophobic drugs. Widely used in cancer chemotherapy, they improve drug solubility, stability, and controlled release while reducing systemic toxicity [21].
2. Dendrimers are highly branched macromolecules offering high drug-loading capacity and surface functionalization for targeting. Effective in controlled drug release, gene delivery, and cancer therapy [22].
3. Polymeric nanoparticles are constructed from biodegradable polymers, these nanocarriers enable controlled drug release and surface modifications for enhanced biocompatibility and targeting. They are applicable in cancer therapy, vaccine delivery, and beyond.
4. Gold nanoparticles are biocompatible and easily functionalized, gold nanoparticles excel in imaging and therapeutic applications. They are particularly effective in photothermal therapy by converting light to heat to destroy cancer cells [23].
5. Carbon nanotubes are cylindrical nanostructures with high surface area and cell membrane penetration capability. Functionalized carbon nanotubes are promising for delivering drugs, genes, and proteins with reduced toxicity [24].
6. Quantum dots are semiconductor nanocrystals with distinctive optical properties, mainly used in imaging applications. When conjugated with drugs, they enable simultaneous imaging and targeted therapy, especially in cancer treatment.

These nanocarriers provide innovative solutions for targeted drug delivery, improving therapeutic outcomes across diverse medical applications [25]. Table 1 shows the summary of nanocarrier types and Figure 1 shows the structure of nanoparticles.

Table 1. Types of nanocarriers and their characteristics

Nanocarrier Type	Material	Size Range(nm)	Drug Loading Capacity	Targeted Capability	Clinical Status
Liposomes	Phospholipids, acylglycerols, and cholesterol	50–200	High	Active/passive	Approved by the FDA was Doxil (liposomal doxorubicin
Polymeric micelles	Amphiphilic block copolymers	10–100	High	Surface modifications/ passive targeting	Approved by FDA example Cremophor EL (polyethylene glycol 35 castor oil), which is used in the formulation of the drug Taxol (paclitaxel), approved in 1992. Additionally, more recent polymeric micelle formulations, such as Marqibo (liposomal vincristine), which utilizes polymeric micelle technology, were approved by the FDA in 2012.
Dendrimers	Polymers	1–10	Moderate	Active	Under research
Solid Lipid Nanoparticles (SLNs)	Solid lipids, which can include triglycerides, fatty acids, and waxes.	Range from 50–1000 nm in diameter, with an average size often around 100–300 nm.	Higher	Passive targeting/active targeting	Under research
Inorganic nanoparticles	*Metals:* commonly used metals include gold (Au), silver (Ag), iron (Fe), and copper (Cu) *Metal oxides:* metal oxides, such as titanium dioxide (TiO_2), zinc oxide (ZnO), and silicon dioxide (SiO_2) *Quantum dots:* semiconductor materials like cadmium selenide (CdSe) and cadmium sulfide (CdS)	1–100	High	Active/passive	FDA approved example is Doxil (liposomal doxorubicin), which incorporates inorganic components and was approved in 1995. Abraxane, a formulation of paclitaxel bound to albumin nanoparticles, was approved in 2005.
Nanoemulsions	Colloidal dispersions consisting of two immiscible liquids, typically oil and water, stabilized by surfactants	20–200	Higher	Active/passive	Approved examples: Restasis (cyclosporine ophthalmic emulsion): this nanoemulsion eye drop formulation,

					approved by the FDA in 2002, Estrasorb (estradiol topical emulsion): Estrasorb, approved by the FDA in 2003
Biodegradable nanocarriers	Combination of polymers, surfactants, and sometimes additional functionalizing agents.	10–300	High	Active or passive	Approved Examples: Doxil (liposomal doxorubicin): approved by the FDA in 1995, Abraxane (paclitaxel protein-bound nanoparticles): approved in 2005,
Polymeric nanoparticles	PLGA, PLA	10–100	High	Passive	Approved examples: Genexol-PM (paclitaxel-loaded polymeric micelle): approved by the FDA in 2007, Onivyde (irinotecan liposomal injection): approved by the FDA in 2015,
Biodegradable nanoparticles	Made from natural or synthetic polymers, such as: • Poly(lactic-co-glycolic acid) (PLGA) • Chitosan • Poly(dimethylmalic acid)	50–300 nm in diameter.	High loading efficiency	Active/passive	FDA approval Example: Genexol-PM (paclitaxel-loaded polymeric micelle): approved in 2007, Onivyde (irinotecan liposomal injection): approved in 2015
Nanospheres	• Polymers • Lipids • Inorganic Materials	100–1000	High loading efficiency	Active targeting	Under experimental
Nanocapules	Natural polysaccharides, synthetic polymers, and lipids.	50–1000	High encapsulation efficiency	Active/passive	FDA approved Examples: Abraxane (paclitaxel protein-bound nanoparticles): Approved by the FDA in 2005, Onpattro (patisiran): approved by the FDA in 2018,

Exosomes	Lipid bilayer, which encapsulates various biomolecules, including proteins, lipids, and nucleic acids	30–150	High loading capacity	Active/passive	Under experimental
Carbon Nanotubes	Carbon atoms	• Single-Walled Carbon Nanotubes (SWCNTs): 1 nm. • Multi-walled carbon nanotubes (MWCNTs): 2 to over 100 nm.	High	Active/passive	Under experimental
Graphene oxide nanoparticles	Presence of oxygen-containing functional groups.	Less than 1 µm	High	Active/passive	Under experimental
Magnetic nanoparticles	Magnetic nanoparticles	1–100	High	Active/passive	FDA approved Example: Ferumoxytol (Feraheme):2009 Resovist (Ferucarbotran):2001
Silica nanoparticles	Silicon dioxide	1–100	High	Active/passive	Under developing
Chitosan nanoparticles	Chitosan, a biopolymer derived from chitin.	50–500 nm in diameter	High	Active	Under research
Albumin nanoparticle	Human serum albumin (HSA) or bovine serum albumin (BSA).	50–200 nm in diameter.	High	Active	FDA approved Examples: Nab-Paclitaxel (Abraxane): approved in 2005 Daxxify (DaxibotulinumtoxinA-lanm): approved in 2022
Microneedles	Metals, polymers, and ceramics.	50–900 µm in length.	High	Active/passive	FDA approved examples: Microneedle Patches for Influenza Vaccination: approved in 2021 Microneedle Patches for Zoster Vaccine: approved in 2022
Nanocrystals	Semiconductors, metals, and oxides.	1–100	High	Active/passive	They are not directly approved by FDA but few examples of FDA-approved products that may

					incorporate nanocrystal technology Abraxane (nab-paclitaxel): approved by the FDA in 2005 Onivyde (irinotecan liposome injection): approved by the FDA in 2015
Quantum dots	Semiconductor materials, including cadmium selenide (CdSe), cadmium telluride (CdTe), indium phosphide (InP), and lead sulfide (PbS).	1–10	High	Active/passive	Under research
Nanofibers	Synthetic polymers, natural polymers, and composite materials.	50–500	High	Active	Under research
Antibody-targeted nanocarriers	Biodegradable polymers, such as poly(lactide-co-glycolide) (PLGA) or chitosan.	25 to several hundred nanometers	High	Active	FDA approved Examples: Amivantamab: approved on May 21, 2021 Secukinumab: approved in 2021
Micelle-forming amphiphilic copolymers	Hydrophilic and hydrophobic blocks.	10–300 nm in diameter,	High	Active	Under research
Hybrid nanocarriers	Lipids and polymers.	200–250	High	Active	Under research



Figure 1. Structure of nanoparticle.
(Source: Image created by Meta AI 2024 (llama 3.2) text to image generating model).

Nanotechnology-driven drug delivery systems present numerous advantages but also encounter several challenges. The following outlines the benefits and potential limitations of this innovative approach.

Advantages of Nanoparticles in Drug Delivery

1. *Targeted Delivery:* Accurately targets diseased cells, improving treatment effectiveness and minimizing systemic toxicity.
2. *Enhanced Bioavailability:* Improves solubility and stability of poorly soluble drugs [26].
3. *Controlled Release:* Enables stimuli-responsive, precise drug release [27].
4. *Prolonged Circulation:* Extends bloodstream circulation, enhancing drug accumulation at target sites.
5. *Combination Therapies:* Allows co-delivery of multiple agents for complex diseases like cancer [28].

Challenges in Nanoparticle Drug Delivery

1. *Biocompatibility:* Potential toxicity and long-term health effects require thorough evaluation.
2. *Manufacturing:* Scalable, consistent production is challenging due to complex synthesis processes [29].
3. *Regulatory Issues:* Evolving frameworks struggle to address the novel properties of nanomaterials.
4. *Stability:* Sensitivity to environmental conditions affects therapeutic efficacy and storage.
5. *Cost:* High development and manufacturing expenses limit accessibility [30].

Current Trends in Nanotechnology-Driven Drug Delivery

Targeted Drug Delivery via Nanotechnology

Nanotechnology enables precise delivery of therapeutics to specific cells, enhancing efficacy and reducing off-target effects.

1. *Passive Targeting:* Nanoparticles take advantage of the EPR effect, allowing them to accumulate in tumor tissues due to leaky blood vessels and inadequate lymphatic drainage. Passive targeting is shown in Figure 2 [31].
2. *Active Targeting:* Nanoparticles can be modified on their surface with targeting ligands, such as antibodies, peptides, or small molecules, which selectively bind to receptors that are overexpressed on tumor cells or in the tumor blood vessels. This active targeting strategy enhances the precision of drug delivery to the desired site [32]. Active targeting is shown in Figure 3.
3. *Transcytosis:* Nanoparticles cross barriers like the BBB via vesicular transport, enhanced by surface modifications or cell-penetrating peptides [33].
4. *Carrier-Mediated Transport:* Nanoparticles mimic endogenous molecules to utilize specific transporters for active barrier crossing [34].



Figure 2. Targeted drug delivery by passive targeting.
(*Source: Image created by Meta AI 2024 (llama 3.2) text to image generating model*).



Figure 3. Targeted drug delivery by active targeting.
(*Source: Image created by Meta AI 2024 (llama 3.2) text to image generating model*).

These mechanisms improve therapeutic precision and outcomes in diseases like cancer and kidney disorders [35].

Nanotechnology in Personalized Medicine

1. *Customized Therapeutics:* Nanocarriers tailor treatments to individual genetic and phenotypic profiles, enhancing efficacy and reducing side effects [36].
2. *Pharmacogenomics Integration:* Nanotechnology aids in identifying genetic markers to optimize drug selection and dosage [37].
3. *Enhanced Drug Delivery:* Nanocarriers improve solubility, stability, and bioavailability while enabling controlled drug release [38].
4. *Theranostics:* Combines diagnostics and therapy for real-time monitoring and adaptable treatments [39].
5. *Advanced Diagnostics:* Nanosensors and imaging agents enhance early detection and disease monitoring.

These innovations deliver precise, efficient, and personalized treatments, improving outcomes and care quality [40].

Stimuli-Responsive Nanoparticles

1. *pH-Responsive:* Release drugs in acidic tumor environments, reducing toxicity and enhancing efficacy [41].
2. *Temperature-Responsive:* Trigger drug release via localized heating, ideal for hyperthermia treatments.
3. *Light-Responsive:* Enable precise drug release using specific light wavelengths, protecting healthy tissues.
4. *Redox-Responsive:* React to oxidative tumor environments, ensuring targeted drug delivery [42].

Controlled Release Systems

1. *Polymeric Nanoparticles:* Enable sustained drug release with adjustable kinetics for prolonged effects and reduced dosing frequency [43].
2. *Electromagnetic Stimuli:* Trigger precise drug release using external fields, improving tissue-specific targeting [44].

3. *Combination Systems:* Multi-stimuli-responsive nanoparticles optimize controlled release, enhancing cancer therapy efficacy and reducing side effects [45].

Applications of Nanotechnology in Cancer Treatment

1. *Targeted Delivery:* Nanoparticles selectively target cancer cells using mechanisms like the EPR effect or receptor-specific ligands, minimizing damage to healthy tissues [46].
2. *Improved Solubility:* Encapsulation enhances the solubility and stability of poorly soluble anticancer drugs, increasing bioavailability.
3. *Controlled Release:* Stimuli-responsive nanoparticles release drugs precisely at target sites, optimizing efficacy and reducing side effects [47].
4. *Combination Therapies:* Enable co-delivery of multiple agents to target diverse cancer pathways and combat drug resistance.
5. *Immunotherapy Boost:* Nanoparticles enhance immune responses by delivering immunotherapeutic agents or modulating tumor-related immune suppression [48].

Examples of Approved Nanomedicines

1. *Doxil:* Liposomal doxorubicin targets tumors, reducing cardiotoxicity. Used for breast cancer, ovarian cancer, and multiple myeloma.
2. *Abraxane:* Albumin-bound paclitaxel enhances solubility, improving treatment for metastatic breast cancer, lung cancer, and pancreatic cancer [49].
3. *Onivyde:* Liposomal irinotecan improves pharmacokinetics, reducing toxicity for pancreatic cancer treatment.
4. *Vyxeos:* Liposomal cytarabine and daunorubicin improve treatment for acute myeloid leukemia, enhancing therapeutic outcomes.

Nanotechnology also shows promise for managing diabetes, cardiovascular diseases, and neurodegenerative disorders [50].

Nanotechnology in Diabetes Management

- *Drug Delivery:* Nanoparticles enable controlled, oral insulin delivery, improving pharmacokinetics and patient compliance [51].
- *Glucose Monitoring:* Nanosensors using materials like carbon nanotubes and gold nanoparticles provide real-time, sensitive glucose level detection [52].

Nanotechnology in Cardiovascular Diseases

- *Targeted Drug Delivery:* Nanoparticles target atherosclerotic plaques, delivering anti-inflammatory drugs to improve the treatment of atherosclerosis and myocardial infarction.
- *Imaging and Diagnostics:* Magnetic nanoparticles and quantum dots enhance imaging techniques, improving early detection and monitoring of cardiovascular diseases [53].

Nanotechnology in Neurodegenerative Disorders

- *Drug Delivery Across the BBB*: Nanocarriers like liposomes and dendrimers enable effective drug transport across the BBB, ensuring therapeutic concentrations in the brain [54].
- *Neuroprotection and Regeneration*: Nanotechnology aids neuroprotection by delivering agents that reduce oxidative stress and inflammation, promoting neuronal repair in neurodegenerative diseases and spinal cord injuries [55].

Innovative Techniques and Materials in Nanotechnology

Emerging Nanomaterials for Drug Delivery

- *Graphene:* A high surface area, mechanically strong nanomaterial, graphene and its derivative graphene oxide (GO) enable targeted drug delivery and time-controlled release, with versatile applications in drug delivery systems [56].

- *Nanodiamonds:* Known for biocompatibility and high surface area, nanodiamonds are used for targeted delivery of anticancer drugs, proteins, and nucleic acids, with functionalization to enhance cellular uptake [57–58].
- *Metal-Organic Frameworks (MOFs):* These porous materials offer high surface area and tunable pore sizes, ideal for encapsulating therapeutic agents and enabling controlled drug release, positioning them as key materials in drug delivery [59–60].

Advanced Manufacturing Techniques in Nanoparticle Synthesis

- *3D Printing:* Enables the production of precise microfluidic devices and viscoelastic nanoparticle suspensions, improving nanoparticle uniformity and expanding integration into advanced composites [61].
- *Microfluidics:* Facilitates the controlled synthesis of nanoparticles via rapid reactant mixing, enhancing precision and enabling novel material applications [62].
- *Self-Assembly:* Uses intrinsic material properties or templates to create structured nanoparticles with enhanced functionality for diverse applications [63].

Multifunctional Nanocarriers (Theranostics)

- *Graphene-Based Nanocarriers:* Offer high drug loading and dual functionality for drug delivery and imaging, advancing personalized medicine [64].
- *Nanodiamonds:* Combine biocompatibility with imaging capabilities, enabling targeted therapy and real-time monitoring [65].
- *Metal-Organic Frameworks (MOFs):* Support controlled release and imaging integration, providing a platform for simultaneous therapy and diagnostics [66].

Applications in Cancer Therapy

Theranostic nanocarriers combine treatment and diagnostics, improving outcomes through targeted delivery and real-time monitoring, revolutionizing personalized cancer therapy [67].

Safety, Toxicity, and Regulatory Considerations

The unique properties of nanomaterials require careful evaluation of biocompatibility and potential toxicity to ensure safe biomedical applications [68].

Potential Toxicity Mechanisms

Nanomaterials may induce toxicity through several mechanisms:

1. *Oxidative Stress:* Some nanomaterials can produce reactive oxygen species (ROS), causing oxidative stress that may lead to cellular damage [69].
2. *Inflammation:* Exposure to nanomaterials may provoke inflammatory responses, potentially causing tissue damage and contributing to chronic health conditions [70].
3. *Genotoxicity:* Some nanomaterials have been observed to interact with DNA, raising the possibility of genetic mutations and an increased risk of carcinogenesis [71].
4. *Organ-Specific Toxicity:* Depending on their composition and route of exposure, nanomaterials can accumulate in specific organs, such as the liver, lungs, or brain, leading to organ-specific toxic effects [72].

Assessing Biocompatibility

To ensure the safe use of nanomaterials in biomedical applications, thorough biocompatibility testing is required, including a range of in vitro and in vivo studies to assess any potential toxic effects. Critical aspects of biocompatibility assessment include:

1. *Cytotoxicity:* In vitro assays using cell lines are conducted to evaluate the cytotoxic effects of nanomaterials, assessing parameters, such as cell viability, proliferation, and apoptosis.
2. *Genotoxicity:* The potential of nanomaterials to cause DNA damage is examined through assays like the comet assay and the micronucleus test.

3. *Acute and Chronic Toxicity:* Animal studies are employed to assess the acute and chronic toxicological profiles of nanomaterials, with evaluations including mortality rates, clinical symptoms, changes in body weight, and histopathological alterations in organs.
4. *Biodistribution and Clearance:* Studies on the biodistribution and clearance of nanomaterials are crucial for understanding their in vivo fate and potential for organ-specific accumulation [73].

Strategies to Enhance Biocompatibility

Several strategies are employed to improve the biocompatibility of nanomaterials:

1. *Surface Modification:* Functionalization of nanomaterials with biocompatible molecules, such as polyethylene glycol (PEG), can reduce protein adsorption, opsonization, and immune clearance, thereby enhancing their biocompatibility.
2. *Biodegradable Materials:* The use of biodegradable materials, such as polymers and lipids, ensures that nanomaterials are gradually broken down and cleared from the body, reducing the risk of long-term toxicity [74].
3. *Targeted Delivery:* Designing nanomaterials with specific targeting ligands can minimize off-target effects and limit exposure to healthy tissues, enhancing therapeutic specificity and safety.
4. *Rigorous Testing:* Ensuring nanomaterial safety in biomedical applications requires rigorous in vitro and in vivo testing, adherence to evolving regulatory standards, and collaboration among scientists, clinicians, and regulators. Adapting guidelines to the distinct properties of nanomaterials is crucial for ensuring the safe and effective progress of nanomedicine [75].

Regulatory Challenges

1. *Lack of Unified Definitions:* The absence of a universal definition for "nanomedicine" leads to inconsistent classification and regulation across regions [76].
2. *Complexity:* The intricate nature of nanomedicines and variable physicochemical properties challenge standardized safety and efficacy evaluations [77].
3. *Safety Concerns:* Unique nanomaterial properties can cause toxicities like oxidative stress and inflammation, necessitating rigorous toxicological studies and further research.
4. *Follow-On Products:* Regulatory pathways for nanomedicine generics are complex, requiring tailored approaches to address formulation differences.
5. *Harmonized Standards:* Collaboration among stakeholders is vital to develop unified, science-based standards for advancing nanomedicine [78].

Approval Process for Nanomedicines

The approval process for nanomedicines generally involves several critical steps:

1. *Preclinical Studies:* Comprehensive in vitro and animal studies evaluate nanomedicine safety, efficacy, and pharmacokinetics before clinical trials.
2. *Clinical Trials:* Conducted in phases (I-III), these trials determine safety, optimal dosage, and potential adverse effects in humans.
3. *Regulatory Submission:* A detailed submission, including manufacturing, quality control, and clinical data, is reviewed by regulatory agencies for approval.
4. *Post-Market Surveillance:* Ongoing monitoring ensures long-term safety and efficacy, addressing unforeseen adverse effects.

Collaboration among regulators, industry, and academia is critical for advancing nanomedicine, addressing ethical concerns, and shaping public trust [79].

Public Perception

1. *Awareness and Understanding:* Limited public knowledge about nanotechnology leads to misconceptions and skepticism. Clear communication strategies are essential to build trust and enhance understanding [80].
2. *Fear of the Unknown:* Concerns about safety, environmental impact, and health effects, amplified by a lack of transparency, contribute to public apprehension [81].

3. *Cultural and Ethical Perspectives:* Acceptance varies by cultural and ethical values, emphasizing the need for inclusive stakeholder engagement to address diverse concerns [82].

Ethical Concerns

1. *Health and Safety Risks*: Rigorous testing and ethical oversight are essential to mitigate the potential toxicity of nanomaterials in consumer and medical applications.
2. *Equity and Access*: Ethical frameworks must address disparities to ensure equitable access to nanotechnology benefits across all socioeconomic groups [83].
3. *Environmental Impact*: Sustainable practices throughout the nanomaterial lifecycle are vital to minimize environmental harm and promote responsible innovation [83].
4. *Privacy and Surveillance*: Ethical guidelines must safeguard privacy while enabling nanotechnology's benefits in healthcare and security [84].

Future Directions and Emerging Research

Future advancements in nanocarriers, particularly those involving nanorobots and artificial intelligence (AI)-driven drug delivery systems, have the potential to revolutionize medical treatment. These advancements hold the potential to improve the accuracy, effectiveness, and personalization of therapeutic treatments. This section offers a speculative overview of these next generation nanocarriers [85].

Nanorobots

1. *Autonomous Drug Delivery:* Nanorobots are being engineered to navigate biological environments autonomously. These micro/nanorobots can be propelled by mechanisms, such as chemical reactions or external fields, enabling them to target specific sites within the body, including tumors. By targeting therapeutic payloads directly to diseased tissues, these nanorobots can enhance treatment effectiveness and minimize the systemic side effects commonly seen with traditional drug delivery methods [86].
2. *Motile-Targeting Platforms:* The development of motile-targeting drug delivery systems using nanorobots marks a significant advancement. These systems can actively seek out and deliver drugs to designated locations, such as tumor sites, thereby enhancing targeting efficiency beyond conventional passive mechanisms. This capability could lead to more effective cancer treatments and reduced off-target effects.
   Biocompatibility and Safety: Future nanorobots are expected to incorporate advanced materials and designs that enhance biocompatibility and minimize toxicity. Ongoing research aims to optimize interactions between these nanorobots and biological systems to ensure their safe operation within the human body without eliciting adverse immune responses [87].

AI-Driven Drug Delivery Systems

1. *Smart Drug Delivery:* The integration of AI into drug delivery systems enables real-time monitoring and adaptive drug release. AI algorithms can analyze patient data, including biomarkers and imaging results, to dynamically optimize dosing schedules and delivery routes. This personalized approach can improve treatment results and reduce the likelihood of adverse effects.
2. *Predictive Modeling:* AI can be utilized to predict the behavior of nanocarriers in vivo, including their distribution, metabolism, and elimination. By leveraging machine learning algorithms, researchers can model how various nanomaterial characteristics influence their performance, facilitating the design of more effective and safer nanocarriers for specific therapeutic applications [88].
3. *Data Integration and Decision Support:* AI-driven systems can integrate extensive data from clinical trials, patient records, and laboratory studies to support decision-making in drug development. This capability can expedite the identification of promising nanocarrier formulations and streamline the regulatory approval process by providing comprehensive safety and efficacy profiles.

Challenges and Future Outlook

1. *Regulatory Framework:* Clear guidelines for nanorobots and AI-driven systems are needed, requiring collaboration among regulators, industry, and academia.
2. *Ethical Implications:* Privacy, consent, and fair access should be prioritized to ensure responsible development and uphold public trust [89].
3. *Public Perception:* Transparent communication about benefits and risks is essential to gain support from patients and healthcare providers.

Advancements in nanorobots and AI-driven systems promise transformative, personalized medical therapies but require careful navigation of regulatory, ethical, and societal challenges [90].

Bridging the Lab-to-Clinic Gap in Nanotechnology

The Transition of Nanotechnology to Clinical Use Faces Key Obstacles

1. *Nanomaterial Complexity:* Variations in size, shape, and properties complicate safety and efficacy evaluations, while regulatory delays hinder progress.
2. *Regulatory Hurdles:* The lack of standardized definitions and clear guidelines creates challenges for nanomedicine development and approval [91].
3. *Preclinical Limitations:* Conventional models often fail to predict human responses, highlighting the need for advanced, human-relevant models.
4. *Funding Constraints:* Limited resources for translational research slow the progression from lab discoveries to clinical trials.

Addressing these barriers is critical to advancing nanotechnology's clinical integration [92].

Strategies to Bridge the Lab-to-Clinic Gap in Nanotechnology

- *Collaborative Efforts*: Foster partnerships among academia, industry, and regulators to align research with clinical needs and streamline nanomedicine development.
- *Regulatory Innovation*: Develop adaptive guidelines tailored to nanomedicines, ensuring safety while expediting approval processes [93].
- *Advanced Preclinical Models*: Invest in organ-on-a-chip and patient-derived xenografts to enhance the predictability of clinical outcomes.
- *AI Integration*: Utilize AI for nanocarrier design, behavior prediction, patient selection, and data analysis to optimize drug development [94].
- *Public Engagement*: Build trust through transparent communication about nanomedicine benefits and risks, fostering support and trial participation.

Addressing these areas is crucial for translating nanotechnology into impactful medical therapies [95].

International Research Collaborations in Nanotechnology: Trends and Impacts

International research collaborations in nanotechnology are pivotal in advancing the field, facilitating knowledge exchange, and accelerating innovation. These collaborations involve a range of stakeholders, including academic institutions, industry partners, and government agencies, and span diverse applications from healthcare to agriculture. The following outlines the key trends and impacts of these collaborations:

Global Trends in Nanotechnology Research

1. *Increased Publication and Collaboration:* Recent bibliometric analyses reveal a marked increase in publications related to nanotechnology across various domains, such as healthcare, pain management, and agriculture. For instance, China has emerged as a leading contributor to nanotechnology research, while the United States leads in citation impact. This dynamic highlight a collaborative landscape where different nations leverage each other's strengths to advance the field [96].

2. *Focus on Interdisciplinary Research:* Nanotechnology's intrinsic interdisciplinary nature necessitates the integration of insights from fields, such as physics, chemistry, biology, and engineering. International collaborations often unite experts from these diverse domains, fostering innovative solutions that might not arise within isolated disciplines. This trend is notably evident in cancer nanotechnology, where hybrid models incorporating multiple scientific perspectives are being developed to enhance diagnostics and therapeutic strategies.
3. *Network Development:* The growth of collaborative networks is essential for propelling nanotechnology research forward. Evidence indicates an increasing collaboration index among researchers, reflecting a trend towards more extensive partnerships across institutions and countries. For example, research on nanotechnology applications in meat production has demonstrated a collaborative index of 3.31, underscoring the trend of researchers working together to address complex issues in food security and sustainability [97].

Impact of International Collaborations in Nanotechnology

1. *Accelerated Innovation:* Collaborative efforts speed up the development of new nanotechnology applications, especially in drug delivery and nanomedicine, by combining resources and expertise.
2. *Enhanced Funding:* International collaborations attract diverse funding from government, private sector, and research initiatives, supporting large-scale projects [98].
3. *Standardization:* Sharing findings across institutions fosters the development of unified guidelines, improving safety, efficacy, and regulatory compliance [99].
4. *Global Knowledge Exchange:* Cross-border collaboration facilitates the exchange of insights, addressing global challenges like health disparities and sustainability.

These partnerships are crucial for advancing nanotechnology and offering solutions to global challenges [100].

Anticipated Impact of Nanotechnology on Healthcare

Nanotechnology is set to revolutionize healthcare by improving disease prevention, diagnosis, and treatment:

- *Early Disease Detection:* Nanomaterials can identify disease biomarkers, enabling early diagnosis and better outcomes [101].
- *Targeted Drug Delivery:* Nanocarriers deliver drugs directly to diseased cells, minimizing side effects and enhancing effectiveness, particularly in cancer treatment.
- *Regenerative Medicine:* Nanotechnology supports tissue repair and organ regeneration, potentially replacing damaged tissues [102].
- *Personalized Medicine:* Treatments are customized based on genetic profiles, improving effectiveness and minimizing adverse effects [103].
- *Biocompatible Implants:* Nanomaterials improve medical implants' integration and reduce infection risks.

These innovations promise more effective and personalized healthcare but addressing ethical and regulatory issues is vital for safe development [104].

CASE STUDIES

FDA-Approved Nanomedicines

As of 2024, several nanotechnology-based therapeutics have received approval from the U.S. Food and Drug Administration (FDA) for clinical use. These nanomedicines leverage the unique properties of nanomaterials to improve drug delivery, boost therapeutic effectiveness, and reduce adverse effects.

Below are examples of FDA-approved nanomedicines.

Antibody-Drug Conjugates (ADCs)

1. *Brentuximab Vedotin (Adcetris):* This ADC consists of an anti-CD30 monoclonal antibody linked to the microtubule-disrupting agent monomethyl auristatin E (MMAE). It is indicated for the treatment of Hodgkin lymphoma and systemic anaplastic large-cell lymphoma [105].

2. *Trastuzumab Emtansine (Kadcyla):* This ADC consists of the HER2-targeted monoclonal antibody trastuzumab linked to the cytotoxic agent DM1. It is approved for the treatment of HER2-positive metastatic breast cancer [106].

Liposomal Formulations

1. *Doxorubicin Hydrochloride Liposome Injection (Doxil):* This formulation involves encapsulating the chemotherapeutic agent doxorubicin within liposomes. It is approved for treating ovarian cancer, multiple myeloma, and AIDS-related Kaposi's sarcoma [107].
2. *Daunorubicin Citrate Liposome Injection (DaunoXome):* This formulation involves the liposomal encapsulation of the chemotherapeutic agent daunorubicin. It is indicated for the treatment of advanced HIV-associated Kaposi's sarcoma [108].

Protein-Based Nanoparticles

Paclitaxel Protein-Bound Particles (Abraxane)

This formulation uses albumin-bound nanoparticles to deliver paclitaxel, a chemotherapeutic agent. It is approved for the treatment of metastatic breast cancer, non-small cell lung cancer, and pancreatic cancer [109].

Polymeric Micelles

Vincristine Sulfate Liposome Injection (Marqibo)

This formulation uses sphingomyelin/cholesterol liposomes to deliver vincristine, a chemotherapy drug and is approved for treating Philadelphia chromosome-negative acute lymphoblastic leukemia.

These FDA-approved nanomedicines illustrate the capability of nanotechnology to improve drug delivery systems and enhance therapeutic outcomes. As research progresses, further advancements and additional nanotechnology-based therapeutics are anticipated to enter the market [110].

Promising Drug Delivery Systems in Clinical Trials Nanotechnology Is Advancing Drug Delivery, Particularly in Oncology and Chronic Disease Management, Through the Following Systems

1. *Functionalized Nanoparticles:* Personalized nanoparticles target tumor cells based on specific biomarkers, enhancing precision and minimizing damage to healthy tissue [111].
2. *Nanoparticle-Encapsulated Chemotherapeutics:* Nanoparticles encapsulating chemotherapy drugs improve solubility, stability, and reduce toxicity.
3. *Antibody:* ADCs pair monoclonal antibodies with cytotoxic drugs to more precisely target cancer cells, minimizing off-target effects [112].
4. *Nanorobots and Smart Delivery Systems:* Nanorobots deliver drugs to specific sites, using external stimuli to release payloads precisely when needed.
5. *Combination Therapies:* Nanocarriers are used to deliver multiple drugs simultaneously, enhancing outcomes and addressing drug resistance [113].
6. *Gene Delivery Systems:* Nanoparticles deliver nucleic acids, like siRNA and mRNA, to target genetic pathways for treating diseases.

These innovative systems are poised to transform healthcare by improving therapeutic efficacy and minimizing adverse effects [114].

Failures and Lessons in Nanotechnology-Driven Drug Delivery Systems Several Challenges Have Emerged in the Development of Nanomedicines, Offering Key Insights

1. *Inadequate Targeting*: Early nanomedicines struggled with effectively targeting tumors due to biological barriers.
   - *Lesson*: Advanced targeting strategies, like specific ligands or antibodies, are essential for overcoming tumor heterogeneity [115].
2. *Safety and Toxicity*: Some nanomedicines caused unexpected toxicity, especially when accumulating in non-target organs.
   - *Lesson:* Rigorous toxicological evaluations and more accurate preclinical models are needed [116].

3. *Regulatory Challenges*: Inconsistent regulatory frameworks delayed or rejected some nanomedicines due to insufficient data.
   - *Lesson:* Harmonized guidelines and collaborative efforts are needed to address the unique nature of nanomedicines.
4. *Manufacturing and Scalability Issues*: Nanomedicines that worked in small-scale studies faced stability and quality issues in large-scale production.
   - *Lesson:* Robust manufacturing processes and quality-by-design principles are necessary for consistency [117].
5. *Overestimation of Efficacy*: Clinical outcomes sometimes did not meet expectations, highlighting the complexity of biological systems.
   - *Lesson:* Realistic expectations and continuous feedback between preclinical and clinical studies are critical [118].

Learning from these failures will help refine the development of safer, more effective nanomedicines.

CONCLUSIONS

Nanotechnology has become a transformative force in drug delivery systems, significantly influencing the medical field with its precision, efficiency, and ability to deliver targeted therapeutic interventions. Its innovations span a wide range of applications, including targeted drug delivery, enhanced solubility, and stimuli-responsive systems, which collectively represent significant advancements in treatment efficacy while mitigating side effects. The development of nanoparticles tailored to specific cells, improved drug stability, and responsiveness to environmental triggers has particularly revolutionized oncology by enhancing targeting and effectiveness. Despite this progress, challenges persist, such as ensuring biocompatibility, scaling up manufacturing processes, and navigating regulatory landscapes. Continued research and technological progress are essential to overcoming these challenges, with the potential to lead to more personalized and effective treatments that could enhance patient outcomes and transform therapeutic practices. Additionally, nanotechnology has shown remarkable potential in managing chronic diseases through engineered nanoparticles for insulin delivery, glucose monitoring, targeted cardiovascular treatments, and neurodegenerative disease management. Emerging materials like graphene and nanodiamonds offer new avenues for integrated drug delivery and diagnostics. The advent of nanorobots and AI-driven systems further enhances treatment precision and personalization, though their integration requires careful attention to regulatory and ethical considerations. Bridging the gap between research and clinical application remains essential, with strategies focusing on improved preclinical models, adaptive regulatory frameworks, and global research collaboration. The progress of FDA-approved nanomedicines, such as ADCs and liposomal formulations, underscores the transformative potential of nanotechnology. Addressing the challenges of effective targeting, safety, toxicity, and scalability will be crucial in harnessing its full promise, ultimately advancing healthcare and paving the way for successful, innovative treatments. This review highlights the transformative impact of nanotechnology on drug delivery systems, emphasizing its role in enhancing treatment precision, efficacy, and personalization across a range of medical conditions. The advancements in nanoparticle design, including targeted delivery, improved solubility, and stimuli-responsive systems, have significantly advanced therapeutic outcomes and minimized side effects, particularly in oncology and chronic disease management. However, future progress hinges on addressing critical challenges, such as biocompatibility, scalability of manufacturing processes, and regulatory hurdles. Continued research is needed to develop nanoparticles with improved targeting capabilities, ensure long-term safety, and streamline production methods. Integration of AI and nanorobotics offers promising avenues for optimizing real-time monitoring and adaptive therapies. Enhancing preclinical models and fostering global collaborations will further bridge the gap between research and clinical applications, driving innovation and ensuring that the full potential of nanotechnology is realized for more effective and personalized treatments.

Conflict of Interest

The authors declare that they have no conflict of interest.

REFERENCES

1. Nikam A, Patil A, Magdum C. Nanotechnology: overview and its application. Asian J Pharm Technol. 2021;11(4):293–5.
2. Omietimi HB, Afolalu SA, Kayode JF, Monye SI, Lawal SL, Emetere ME. An overview of nanotechnology and its application. E3S Web Conf. 2023;391:01079.
3. Cheng HN, Doemeny LJ, Geraci CL, Grob Schmidt D. Nanotechnology overview: Opportunities and challenges. In: Nanotechnology: Delivering on the Promise Volume 1. Washington, DC: American Chemical Society; 2016. p. 1–12.
4. Mosleh-Shirazi S, Abbasi M, Moaddeli MR, Vaez A, Shafiee M, Kasaee SR, et al. Nanotechnology advances in the detection and treatment of cancer: an overview. Nanotheranostics. 2022;6(4):400.
5. Arora S, Murmu G, Mukherjee K, Saha S, Maity D. A comprehensive overview of nanotechnology in sustainable agriculture. J Biotechnol. 2022;355:21–41.
6. Nikam A, Patil A, Magdum C. Nanotechnology: overview and its application. Asian J Pharm Technol. 2021;11(4):293–5.
7. Mosleh-Shirazi S, Abbasi M, Moaddeli MR, Vaez A, Shafiee M, Kasaee SR, et al. Nanotechnology advances in the detection and treatment of cancer: an overview. Nanotheranostics. 2022;6(4):400.
8. Omietimi HB, Afolalu SA, Kayode JF, Monye SI, Lawal SL, Emetere ME. An overview of nanotechnology and its application. E3S Web Conf. 2023;391:01079.
9. Cheng HN, Doemeny LJ, Geraci CL, Grob Schmidt D. Nanotechnology overview: Opportunities and challenges. In: Nanotechnology: Delivering on the Promise Volume 1. Washington, DC: American Chemical Society; 2016. p. 1–12.
10. Arora S, Murmu G, Mukherjee K, Saha S, Maity D. A comprehensive overview of nanotechnology in sustainable agriculture. J Biotechnol. 2022 Aug 20;355:21-41.Nikam A, Patil A, Magdum C. Nanotechnology: Overview and its application. Asian Journal of Pharmacy and Technology. 2021;11(4):293-5.
11. Fissell WH. What is nanotechnology? Adv Chronic Kidney Dis. 2013;20(6):452–3.
12. Balogun OD, Ayo-Farai O, Ogundairo O, Maduka CP, Okongwu CC, Babarinde AO, et al. Innovations in drug delivery systems: a review of the pharmacist's role in enhancing efficacy and patient compliance. World J Adv Res Rev. 2023;20(3):1268–82.
13. Cheng HN, Doemeny LJ, Geraci CL, Grob Schmidt D. Nanotechnology overview: Opportunities and challenges. In: Nanotechnology: Delivering on the Promise Volume 1. Washington, DC: American Chemical Society; 2016. p. 1-12.
14. Omietimi HB, Afolalu SA, Kayode JF, Monye SI, Lawal SL, Emetere ME. An overview of nanotechnology and its application. E3S Web Conf. 2023;391:01079.
15. Gondim BL, da Silva Catarino J, de Sousa MA, de Oliveira Silva M, Lemes MR, de Carvalho-Costa TM, et al. Nanoparticle-mediated drug delivery: blood-brain barrier as the main obstacle to treating infectious diseases in CNS. Curr Pharm Des. 2019;25(37):3983–96.
16. Matoba T, Egashira K. Nanoparticle-mediated drug delivery system for cardiovascular disease. Int Heart J. 2014;55(4):281–6.
17. Hersh AM, Alomari S, Tyler BM. Crossing the blood-brain barrier: advances in nanoparticle technology for drug delivery in neuro-oncology. Int J Mol Sci. 2022;23(8):4153.
18. Tang L, Mei Y, Shen Y, He S, Xiao Q, Yin Y, et al. Nanoparticle-mediated targeted drug delivery to remodel tumor microenvironment for cancer therapy. Int J Nanomedicine. 2021;16:5811–29.
19. Balogun OD, Ayo-Farai O, Ogundairo O, Maduka CP, Okongwu CC, Babarinde AO, et al. Innovations in drug delivery systems: a review of the pharmacist's role in enhancing efficacy and patient compliance. World J Adv Res Rev. 2023;20(3):1268–82.
20. Shah A, Aftab S, Nisar J, Ashiq MN, Iftikhar FJ. Nanocarriers for targeted drug delivery. J Drug Deliv Sci Technol. 2021;62:102426.
21. Wakaskar R. Types of nanocarriers–formulation method and applications. J Bioequiv Availab. 2017;9:10000e77.
22. Bhatia S, Bhatia S. Nanoparticles: types, classification, characterization, fabrication methods and drug delivery applications. In: Natural polymer drug delivery systems: nanoparticles, plants, and algae. 2016:33–93.
23. Ojah AN, Das T. Different types of nanocarriers for targeted treatment of HIV/AIDS. Int J Curr Pharm Res. 2019;66–9.

24. Ng PQ, Ling LS, Chellian J, Madheswaran T, Panneerselvam J, Kunnath AP, et al. Applications of nanocarriers as drug delivery vehicles for active phytoconstituents. Curr Pharm Des. 2020;26(36):4580–90.
25. Balogun OD, Ayo-Farai O, Ogundairo O, Maduka CP, Okongwu CC, Babarinde AO, et al. Innovations in drug delivery systems: a review of the pharmacist's role in enhancing efficacy and patient compliance. World J Adv Res Rev. 2023;20(3):1268–82.
26. Tang L, Mei Y, Shen Y, He S, Xiao Q, Yin Y, et al. Nanoparticle-mediated targeted drug delivery to remodel tumor microenvironment for cancer therapy. Int J Nanomedicine. 2021;5811–29.
27. Jahangirian H, Lemraski EG, Webster TJ, Rafiee-Moghaddam R, Abdollahi Y. A review of drug delivery systems based on nanotechnology and green chemistry: green nanomedicine. Int J Nanomedicine. 2017;2957–78.
28. Matoba T, Egashira K. Nanoparticle-mediated drug delivery system for cardiovascular disease. Int Heart J. 2014;55(4):281–6.
29. Omietimi HB, Afolalu SA, Kayode JF, Monye SI, Lawal SL, Emetere ME. An overview of nanotechnology and its application. E3S Web Conf. 2023;391:01079.
30. Kesharwani P, editor. Nanotechnology-based targeted drug delivery systems for lung cancer. Academic Press; 2019.
31. Güven E. Nanotechnology-based drug delivery systems in orthopedics. Joint Dis Rel Surg. 2021;32(1):267.
32. Tang L, Mei Y, Shen Y, He S, Xiao Q, Yin Y, Xu Y, Shao J, Wang W, Cai Z. Nanoparticle-mediated targeted drug delivery to remodel tumor microenvironment for cancer therapy. Int J Nanomed. 2021;5811–29.
33. Tang L, Li J, Zhao Q, Pan T, Zhong H, Wang W. Advanced and innovative nano-systems for anticancer targeted drug delivery. Pharmaceutics. 2021;13(8):1151.
34. Huang X, Ma Y, Li Y, Han F, Lin W. Targeted drug delivery systems for kidney diseases. Front Bioeng Biotech. 2021;9:683247.
35. Alghamdi MA, Fallica AN, Virzì N, Kesharwani P, Pittalà V, Greish K. The promise of nanotechnology in personalized medicine. J Personal Med. 2022;12(5):673.
36. Herrmann IK, Rösslein M. Personalized medicine: the enabling role of nanotechnology. Nanomedicine. 2016;11(1):1–3.
37. De Matteis L, Martín-Rapún R, de la Fuente JM. Nanotechnology in personalized medicine: a promising tool for Alzheimer's disease treatment. Curr Med Chem. 2018;25(35):4602–15.
38. Ahmad RM, Mohammad M. Towards the use of nanotechnology and pharmacogenomics in personalized medicine. 2021;3(12):689–92
39. Marson D, Laurini E, Aulic S, Fermeglia M, Pricl S. Self-assembling nanotechnology for cancer personalized medicine. Chem Eng Trans. 2019;74:1549–54.
40. Tang Q, Yu B, Gao L, Cong H, Song N, Lu C. Stimuli responsive nanoparticles for controlled anti-cancer drug release. Curr Med Chem. 2018;25(16):1837–66.
41. Balogun OD, Ayo-Farai O, Ogundairo O, Maduka CP, Okongwu CC, Babarinde AO, Sodamade OT. Innovations in drug delivery systems: a review of the pharmacist's role in enhancing efficacy and patient compliance. World J Adv Res Rev. 2023;20(3):1268–82.
42. Longo R, Gorrasi G, Guadagno L. Electromagnetically stimuli-responsive nanoparticles-based systems for biomedical applications: recent advances and future perspectives. Nanomaterials. 2021;11(4):848.
43. An X, Zhu A, Luo H, Ke H, Chen H, Zhao Y. Rational design of multi-stimuli-responsive nanoparticles for precise cancer therapy. ACS Nano. 2016;10(6):5947–58.
44. Thomas RG, Surendran SP, Jeong YY. Tumor microenvironment-stimuli responsive nanoparticles for anticancer therapy. Front Mol Biosci. 2020;7:610533.
45. Chehelgerdi M, Chehelgerdi M, Allela OQ, Pecho RD, Jayasankar N, Rao DP, Thamaraikani T, Vasanthan M, Viktor P, Lakshmaiya N, Saadh MJ. Progressing nanotechnology to improve targeted cancer treatment: overcoming hurdles in its clinical implementation. Mol Cancer. 2023;22(1):169.
46. Gao S, Yang X, Xu J, Qiu N, Zhai G. Nanotechnology for boosting cancer immunotherapy and remodeling tumor microenvironment: the horizons in cancer treatment. ACS Nano. 2021;15(8):12567–603.

47. Zhu C, Ji Z, Ma J, Ding Z, Shen J, Wang Q. Recent advances of nanotechnology-facilitated bacteria-based drug and gene delivery systems for cancer treatment. Pharmaceutics. 2021;13(7):940.
48. Alrushaid N, Khan FA, Al-Suhaimi EA, Elaissari A. Nanotechnology in cancer diagnosis and treatment. Pharmaceutics. 2023;15(3):1025.
49. Tang Q, Yu B, Gao L, Cong H, Song N, Lu C. Stimuli responsive nanoparticles for controlled anti-cancer drug release. Curr Med Chem. 2018;25(16):1837–66.
50. Hosseinzadeh A, Zamani A, Johari HG, Vaez A, Golchin A, Tayebi L, Vafa E, Abbasi M, Amani AM, Chelliapan S, Kamyab H. Moving beyond nanotechnology to uncover a glimmer of hope in diabetes medicine: effective nanoparticle-based therapeutic strategies for the management and treatment of diabetic foot ulcers. Cell Biochem Funct. 2023;41(5):517–41.
51. Shoaib A, Darraj A, Khan ME, Azmi L, Alalwan A, Alamri O, et al. A nanotechnology-based approach to biosensor application in current diabetes management practices. Nanomaterials. 2023;13(5):867.
52. Vargas J, García L, Baena Y. Nanotechnology and herbal products: advances and perspectives in the treatment of diabetes and some of its complications. J Appl Pharm Sci. 2023;13(12):001–14.
53. DiSanto RM, Subramanian V, Gu Z. Recent advances in nanotechnology for diabetes treatment. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2015;7(4):548–64.
54. Gupta R. Diabetes treatment by nanotechnology. J Biotechnol Biomater. 2017;7(3):268.
55. Itoo AM, Vemula SL, Gupta MT, Giram MV, Kumar SA, Ghosh B, et al. Multifunctional graphene oxide nanoparticles for drug delivery in cancer. J Control Release. 2022;350:26–59.
56. Moghadam NB, Avatefi M, Karimi M, Mahmoudifard M. Graphene family in cancer therapy: recent progress in cancer gene/drug delivery applications. J Mater Chem B. 2023;11(12):2568–613.
57. Liu J, Cui L, Losic D. Graphene and graphene oxide as new nanocarriers for drug delivery applications. Acta Biomater. 2013;9(12):9243–57.
58. Oliveira AM, Machado M, Silva GA, Bitoque DB, Tavares Ferreira J, Pinto LA, et al. Graphene oxide thin films with drug delivery function. Nanomaterials. 2022;12(7):1149.
59. Idumah CI. Design, development, and drug delivery applications of graphene polymeric nanocomposites and bionanocomposites. Emerg Mater. 2023;6(3):777–807.
60. Mohammad-Jafari K, Naghib SM. 3D printing of microfluidic-assisted liposomes production for drug delivery and nanobiomedicine: a review. Curr Med Chem. 2024.
61. Yang R, Sun H. A Co-Flow Millifluidic Device for Nanoparticle Synthesis. In: Heat Transfer Summer Conference: American Society of Mechanical Engineers; 2023. p. V001T09A003.
62. Sundaram S, Skouras M, Kim DS, van den Heuvel L, Matusik W. Topology optimization and 3D printing of multimaterial magnetic actuators and displays. Sci Adv. 2019;5(7):eaaw1160.
63. Wang K, Pan W, Liu Z, Wallin TJ, van Dover G, Li S, et al. 3D printing of viscoelastic suspensions via digital light synthesis for tough nanoparticle–elastomer composites. Adv Mater. 2020;32(25):2001646.
64. Feng W, Wen Y, Sun S, Li P, Shi S. Reconfigurable all-oil microfluidic devices by 3D Printing. Small. 2024;20(40):2405892.
65. Gupta R. Diabetes treatment by nanotechnology. J Biotechnol Biomater. 2017;7(3):268.
66. Vargas J, García L, Baena Y. Nanotechnology and herbal products: advances and perspectives in the treatment of diabetes and some of its complications. J Appl Pharm Sci. 2023;13(12):001–14.
67. Itoo AM, Vemula SL, Gupta MT, Giram MV, Kumar SA, Ghosh B, et al. Multifunctional graphene oxide nanoparticles for drug delivery in cancer. J Control Release. 2022;350:26–59.
68. Moghadam NB, Avatefi M, Karimi M, Mahmoudifard M. Graphene family in cancer therapy: recent progress in cancer gene/drug delivery applications. J Mater Chem B. 2023;11(12):2568–613.
69. Hosseinzadeh A, Zamani A, Johari HG, Vaez A, Golchin A, Tayebi L, et al. Moving beyond nanotechnology to uncover a glimmer of hope in diabetes medicine: effective nanoparticle-based therapeutic strategies for the management and treatment of diabetic foot ulcers. Cell Biochem Funct. 2023;41(5):517–41.
70. Vargas J, García L, Baena Y. Nanotechnology and herbal products: advances and perspectives in the treatment of diabetes and some of its complications. J Appl Pharm Sci. 2023;13(12):001–14.Gupta R. Diabetes treatment by nanotechnology. J Biotechnol Biomater. 2017;7(3):268.
71. Shoaib A, Darraj A, Khan ME, Azmi L, Alalwan A, Alamri O, et al. A nanotechnology-based approach to biosensor application in current diabetes management practices. Nanomaterials. 2023 Feb 26;13(5):867.

72. Hosseinzadeh A, Zamani A, Johari HG, Vaez A, Golchin A, Tayebi L, et al. Moving beyond nanotechnology to uncover a glimmer of hope in diabetes medicine: effective nanoparticle-based therapeutic strategies for the management and treatment of diabetic foot ulcers. Cell Biochem Funct. 2023;41(5):517–41.
73. DiSanto RM, Subramanian V, Gu Z. Recent advances in nanotechnology for diabetes treatment. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2015;7(4):548–64.
74. Musazzi UM, Franzè S, Condorelli F, Minghetti P, Caliceti P. Feeding next-generation nanomedicines to Europe: regulatory and quality challenges. Adv Healthc Mater. 2023;12(30):2301956.
75. Mühlebach S. Regulatory challenges of nanomedicines and their follow-on versions: a generic or similar approach? Adv Drug Deliv Rev. 2018;131:122–31.
76. Soares S, Sousa J, Pais A, Vitorino C. Nanomedicine: principles, properties, and regulatory issues. Front Chem. 2018;6:360.
77. Mühlebach S, Borchard G, Yildiz S. Regulatory challenges and approaches to characterize nanomedicines and their follow-on similars. Nanomedicine. 2015;10(4):659–74.
78. Bhattacharya S, Alkharfy KM, Janardhanan R, Mukhopadhyay D. Nanomedicine: pharmacological perspectives. Nanotechnol Rev. 2012;1(3):235–53.
79. Bainbridge WS. Social and ethical implications of nanotechnology. In: Springer Handbook of Nanotechnology; 2004. p. 1135.
80. Patil AS, Parishwad GV, Kale SK, Husainy AS. Modern ethical and societal implications of nanotechnology. EasyChair; 2020.
81. Khan AS, Agajanian A. Incorporating social and ethical implications of nanotechnology in the engineering and technology curricula. In: 2011 ASEE Annual Conference & Exposition; 2011. p. 22–850.
82. Schummer J. 'Societal and ethical implications of nanotechnology': Meanings, interest groups, and social dynamics. In: Nanotechnology challenges: implications for philosophy, ethics, and society; 2006. p. 413–49.
83. Khan A. Ethical and social implications of nanotechnology. QScience Proc. 2014;2015(4):57.
84. Luo M, Feng Y, Wang T, Guan J. Micro-/nanorobots at work in active drug delivery. Adv Funct Mater. 2018;28(25):1706100.
85. Zhang D, Liu S, Guan J, Mou F. "Motile-targeting" drug delivery platforms based on micro/nanorobots for tumor therapy. Front Bioeng Biotechnol. 2022;10:1002171.
86. Kim K, Guo J, Liang Z, Fan D. Artificial micro/nanomachines for bioapplications: biochemical delivery and diagnostic sensing. Adv Funct Mater. 2018;28(25):1705867.
87. Musazzi UM, Franzè S, Condorelli F, Minghetti P, Caliceti P. Feeding next-generation nanomedicines to Europe: regulatory and quality challenges. Adv Healthc Mater. 2023;12(30):2301956.
88. Khan A. Ethical and social implications of nanotechnology. QScience Proc. 2014 Nov 8;2015(4):57.
89. Beech D. Guest editorial: Bridging the gap between laboratory research and clinical practice—dentists doing dental materials research. J Dent Res. 1992;71(5):1266–.
90. Di Rienzo G. Situating the KTA gap in clinical research: foregrounding a discontinuity in practices. Front Psychol. 2023;13:1058845.
91. Khan A. Ethical and social implications of nanotechnology. QScience Proc. 2014 Nov 8;2015(4):57.
92. Foulkes R, Man E, Thind J, Yeung S, Joy A, Hoskins C. The regulation of nanomaterials and nanomedicines for clinical application: current and future perspectives. Biomater Sci. 2020;8(17):4653–64.
93. Musazzi UM, Franzè S, Condorelli F, Minghetti P, Caliceti P. Feeding next-generation nanomedicines to Europe: regulatory and quality challenges. Adv Healthc Mater. 2023 Dec;12(30):2301956.
94. Millagaha Gedara NI, Xu X, DeLong R, Aryal S, Jaberi-Douraki M. Global trends in cancer nanotechnology: a qualitative scientific mapping using content-based and bibliometric features for machine learning text classification. Cancers. 2021;13(17):4417.
95. Sadykova A. Today's key global trends in engineering education: preparing freshmen for nanotechnology. In: 2015 International Conference on Interactive Collaborative Learning (ICL); 2015. p. 508–10. IEEE.

96. Zhu Y, Yao Y, Kuang R, Chen Z, Du Z, Qu S. Global research trends of nanotechnology for pain management. Front Bioeng Biotechnol. 2023;11:1249667.
97. Idamokoro EM, Hosu YS. Global research trends on the use of nanotechnology to boost meat production: a scientometric analysis. Front Res Metr Anal. 2022;6:793853.
98. Khan A. Ethical and social implications of nanotechnology. QScience Proc. 2014 Nov 8;2015(4):57.
99. Bennett-Woods D. Anticipating the impact of nanoscience and nanotechnology in healthcare. In: Nanoscale: Issues and Perspectives for the Nano Century; 2007. p. 295–314.
100. Khan A. Ethical and social implications of nanotechnology. QScience Proc. 2014 Nov 8;2015(4):57.
101. Khan AS, Agajanian A. Incorporating Social and Ethical Implications of Nanotechnology in the Engineering and Technology Curricula. In2011 ASEE Annual Conference & Exposition 2011 Jun 26 (pp. 22-850).
102. Millagaha Gedara NI, Xu X, DeLong R, Aryal S, Jaberi-Douraki M. Global trends in cancer nanotechnology: a qualitative scientific mapping using content-based and bibliometric features for machine learning text classification. Cancers. 2021;13(17):4417.
103. Musazzi UM, Franzè S, Condorelli F, Minghetti P, Caliceti P. Feeding next-generation nanomedicines to Europe: regulatory and quality challenges. Adv Healthc Mater. 2023 Dec;12(30):2301956.
104. Bobo D, Robinson KJ, Islam J, Thurecht KJ, Corrie SR. Nanoparticle-based medicines: a review of FDA-approved materials and clinical trials to date. Pharm Res. 2016;33:2373–87.
105. Foulkes R, Man E, Thind J, Yeung S, Joy A, Hoskins C. The regulation of nanomaterials and nanomedicines for clinical application: current and future perspectives. Biomater Sci. 2020;8(17):4653–64.
106. Yang B, Shi J. Developing new cancer nanomedicines by repurposing old drugs. Angew Chem Int Ed. 2020;59(49):21829–38.
107. Dawidczyk CM, Kim C, Park JH, Russell LM, Lee KH, Pomper MG, Searson PC. State-of-the-art in design rules for drug delivery platforms: lessons learned from FDA-approved nanomedicines. J Control Release. 2014;187:133–44.
108. Sun D, Zhou S, Gao W. What went wrong with anticancer nanomedicine design and how to make it right. ACS Nano. 2020;14(10):12281–90.
109. Kobayashi H, Turkbey B, Watanabe R, Choyke PL. Cancer drug delivery: considerations in the rational design of nanosized bioconjugates. Bioconjug Chem. 2014;25(12):2093–100.
110. Sahakyan N, Haddad A, Richardson S, Forcha-Etieundem V, Christopher L, Alharbi H, Campbell R. Personalized nanoparticles for cancer therapy: a call for greater precision. Anti-Cancer Agents Med Chem. 2017;17(8):1033–9.
111. Foulkes R, Man E, Thind J, Yeung S, Joy A, Hoskins C. The regulation of nanomaterials and nanomedicines for clinical application: Current and future perspectives. Biomaterials science. 2020;8(17):4653-64.
112. Mi P, Cabral H, Kataoka K. Ligand-installed nanocarriers toward precision therapy. Adv Mater. 2020;32(13):1902604.
113. Bobo D, Robinson KJ, Islam J, Thurecht KJ, Corrie SR. Nanoparticle-based medicines: a review of FDA-approved materials and clinical trials to date. Pharm Res. 2016 Oct;33:2373-87.
114. Lorscheider M, Gaudin A, Nakhlé J, Veiman KL, Richard J, Chassaing C. Challenges and opportunities in the delivery of cancer therapeutics: update on recent progress. Ther Deliv. 2021;12(1):55–76.
115. Dai L, Liu J, Luo Z, Li M, Cai K. Tumor therapy: targeted drug delivery systems. J Mater Chem B. 2016;4(42):6758–72.
116. Foulkes R, Man E, Thind J, Yeung S, Joy A, Hoskins C. The regulation of nanomaterials and nanomedicines for clinical application: Current and future perspectives. Biomater Sci. 2020;8(17):4653-64.
117. Musazzi UM, Franzè S, Condorelli F, Minghetti P, Caliceti P. Feeding next-generation nanomedicines to Europe: regulatory and quality challenges. Adv Healthc Mater. 2023 Dec;12(30):2301956.
118. Sahakyan N, Haddad A, Richardson S, Forcha-Etieundem V, Christopher L, Alharbi H, Campbell R. Personalized nanoparticles for cancer therapy: a call for greater precision. Anti-Cancer Agents Med Chem. 2017 Jul 1;17(8):1033-9.

